Tagged with respiratory disease

Jan de Backer – CEO, Fluidda

Belgium Jan de Backer – CEO, Fluidda

Belgium Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of the Belgian firm’s recent history including expansion into the US, how a USD ten million injection of Series A financing…

Marco Ruggiero – General Manager, Chiesi Mexico

Mexico Marco Ruggiero – General Manager, Chiesi Mexico

Mexico Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico. With respiratory diseases, there is sometimes the erroneous perception that they are not as severe or urgent as other…

Interview: Patrice Carayon – CEO, Chiesi France

Pharma Interview: Patrice Carayon – CEO, Chiesi France

Pharma Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities; how they will look to continue to establish themselves in their three main areas: respiratory diseases,…

Dr. Karima Sadok – Country Manager, Chiesi, Algeria

respiratory disease Dr. Karima Sadok – Country Manager, Chiesi, Algeria

respiratory disease The country manager of an Italian pharmaceutical firm talks about the evolution of Algerian health needs and what her firm is doing to counter different forms of respiratory disease prevalent in the country. After eighteen years at Chiesi, what have been your main successes to date? On a personal note,…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page